AbbVie, Genmab Epkinly wins late-stage lymphoma trial
AbbVie and Genmab's Epkinly showed positive Phase 3 results for first-line diffuse large B-cell lymphoma, setting up a challenge to Roche's Polivy.
Palanor Wire · composed from 3 outlets · every claim links to its sources
What happened
AbbVie and Genmab announced positive results from the EPCORE DLBCL-2 Phase 3 trial of Epkinly. 23 The trial demonstrated that Epkinly improved treatment outcomes for first-line diffuse large B-cell lymphoma. 3 Epkinly passed a late-stage trial as a T-cell engager in first-line DLBCL. 2
Why it matters
The results were better-than-expected and could make Epkinly the new undisputed treatment standard in newly diagnosed DLBCL. 1 The successful trial clears the way for a potential market showdown with Roche's Polivy. 2
What to watch
Regulatory review and approval for first-line use of Epkinly in DLBCL. 2 Market competition between Epkinly and Roche's Polivy for first-line DLBCL treatment. 2
Sources · 3
[1]AbbVie, Genmab trot out first-line DLBCL win for Epkinly in challenge to Polivy
Endpoints News
[2]Genmab (GMAB) and AbbVie Phase 3 Trial Shows Epkinly Boosts DLBCL Treatment Outcomes
gurufocus.com · via Marketaux
[3]Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial
BioPharma Dive
Matched signals
Lattice signals Numen pinned to this story at publish time.
Unlock the analytical widgets on every article — signal matches, Trends snapshots, X overlays, agent reasoning — with a Member account.
Upgrade →On X right now
Top engagement posts about this topic, ranked by likes + retweets + quotes.
No high-engagement X posts captured for this topic. Either the topic is too quiet or the upstream API was unavailable when this article published.
Unlock the analytical widgets on every article — signal matches, Trends snapshots, X overlays, agent reasoning — with a Member account.
Upgrade →Your read
How did this article land?
Three sliders. Optional comment. Anonymous is fine.
Open to anyone. One response per reader.